Patricia Pozo Rosich (Headache Unit and Headache Research Group, Vall d’Hebron University Hospital, Barcelona, Spain) talks to us about unmet needs of migraine prevention in Europe and the calcitonin gene-related peptide receptor antagonist, erenumab, in light of it recently receiving a positive CHMP opinion for this indication.
1. What are the major unmet needs of migraine prevention in Europe? (0:12)
2. What is the mechanism of action of erenumab? (0:50)
3. How is erenumab administered? (1:44)
4. Could you tell us a little about the evidence base for the positive CHMP opinion for erenumab for the prevention of migraine? (2:08)
5. Which patients are most likely to benefit from erenumab? (2:39)
Speaker disclosure: Patricia Pozo Rosich serves as a speaker/adviser for Allergan, Almirall, Chiesi, Novartis, Teva and Lilly; she also receives grant support from Allergan.
Filmed at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, June 2018.
Share this Video
Related Videos In Headache Disorders
Peter Goadsby, EAN 2020 – Visual Snow Syndrome
Delighted to interview our valued Editorial Board member Peter Goadsby (King’s College Hospital, London, UK), who shared his expert insights on visual snow syndrome and related updates presented at the 1st Virtual EAN Congress. Questions 1. What are the clinical features and spectrum of severity of visual snow syndrome, and how was it first identified? […]
Uwe Reuter, EAN 2020 – Characteristics of the HER-MES trial in episodic and chronic migraine
Uwe Reuter (Charité Universitätsmedizin Berlin, Germany) talks to us about the first head-to-head randomized, double-blind, double-dummy trial of erenumab and topiramate for the prevention of episodic and chronic migraine (ClinicalTrials.gov Identifier: NCT03828539). Questions 1. What are the unmet needs in the treatment of episodic migraine? (0:05) 2. Could you tell us a little about the […]
Hans-Christoph Diener, EAN 2020 – Chronic Migraine and Medication-Overuse Headache – PROMISE-2
Hans-Christoph Diener (Medical Faculty of the University of Duisburg-Essen, Institute for Medical Informatics, Biometry and Epidemiology, Essen, Germany) talks to us about unmet needs in the treatment of chronic migraine and medication-overuse headache, and shares expert insight on the PROMISE-2 trial, which evaluated the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!